Management Team

Howard C. Coleman, BS, BA, Chairman, CEO, founded the company in 1987 as a forensic and paternity DNA testing laboratory and is a recognized pioneer in DNA testing commercialization. In 2000, he led the company's expansion into the personalized medicine marketplace by implementing the marketing of DNA Drug Sensitivity Testing. Since 2005 Coleman has focused on fostering the development of GeneMedRx and expansion of DNA Drug Sensitivity Testing sales.  

Tia Aulinskas, PhD. MSc, Director, Chief Scientific Officer, co-founded of the company with 20+ years experience as a DNA testing laboratory director. Licenses she has secured for the company include those from the American Society of Blood Banks, The New York State Department of Health. Dr. Aulinskas oversees company laboratory operations including new technology implementation and projects for pharmaceutical companies, hospitals and individual clients.

Gregory Alderson, MBA, CPA, Director, has 20+ years experience in the biotechnology and informatics sectors. Mr. Alderson is CEO of Invizeon Corporation, a provider of advanced communications solutions. He has served in finance, operations and marketing management roles at Microsoft, Raima, General Information, Advanced Products & Technologies and Genetic Systems. He is an outside board member for the company.  

Jessica Oesterheld, MD, Medical Director, is a child psychiatrist and drug interaction expert. She has held several faculty positions and co-authored numerous scientific publications including the best selling Concise Guide to Drug Interaction Principles for Medical Practice. She has served as Medical Director of Pharmacy Management and on the Drug Utilization Committee of MaineCare. Dr Oesterheld is the primary content author of GeneMedRx responsible for expansion and maintenance of the program.

Bob Patterson, MD, Chief Information Officer, has more than 40 years experience as a psychiatrist and has been authoring software to improve patient care since 1983. He is on the attending staff of McLean Hospital and has an appointment at Harvard Medical School. Dr. Patterson is particularly interested in developing programs which help physicians make good clinical decisions including treatment algorithms, quality improvement efforts and smart charting tools. He is responsible for design, programming and maintenance of GeneMedRx’s underlying  algorithm.

Bob Nebel, BS, EMBA, Controller, has more than 30 years of experience in finance and accounting management and administration. His private industry background includes architecture and engineering professional services, wholesale distribution and retail. He oversees the company's accounting department, as well as leading finance and personnel administration for Genelex. Additionally, he leads reinbursement efforts for private, Medicaid and Medicare insurance cases for DNA Drug Sensitivity Testing.

Kristine Ashcraft, BS, Director of Sales and Marketing, a molecular biologist by training, Ms Ashcraft has more than 15 years sales and marketing management experience, including almost a decade of experience at Genelex bringing genetic technologies to market. She is currently enrolled in the Babson College MBA program and is responsible for sales management, including internet sales, and marketing implementation at Genelex.